Beside PGC1a/b, ESRRa has been shown to potentiate a metabolic syndrome by acting downstream of mammalian target of rapamycin (mTOR)7 and also promotes hypoxic adaptation of cancer cells by stabilizing hypoxia inducible factor 1-alpha (HIF1-a) from degradation8. The gene discussed is MTOR; the disease is cancer.